Articles

Affichage des articles associés au libellé trial

Valneva Covid vaccine trial to compare 'old-fashioned' technology with AstraZeneca jab

Image
Senior members of the committee have suggested they could extend the advice to those in their thirties if the background of Covid stays low. Similar potentially linked clots in people who have taken the Johnson & Johnson vaccine have led scientists to speculate that the adenoviral vector platform technology used by both bursts may be the causative factor. Valneva uses inactivated vaccine technology, a format that has been used for the past 100 years to vaccinate billions of people against diseases such as seasonal flu, hepatitis A, polio, and rabies. It injects a version of the live virus that is too weak to cause disease but strong enough to stimulate an immune response. The candidate jab is also given as an adjuvant, which means it contains an ingredient designed to produce a stronger immune response - a technique similar to the flu shots targeted at retirees in annual influenza vaccination campaigns. The shock has now completed the first and second phase safety and immun